Business Development (12)

Challenge A virtual life science company had raised money from angel investors and anticipated a clinical development strategy for their product targeting two major cancer indications. The client...

Challenge A company developing a novel wound care product was embarking on a significant clinical trial program. It was planning an investor exit in the next 24 months and therefore wanted to connect...

Challenge A pharma company that specializes in discovering and developing antibiotics asked us to help expand the search for a development partner in some of its drug candidates.

Challenge A biotech company developing a cell-based cancer immunotherapy was engaged in licensing discussions with a number of major pharma companies and needed valuation support.

Challenge A division of a multinational pharma company needed to evaluate a pipeline agreement with an antibody platform technology company. They wished to understand the overall value of the...

Challenge A biotech company needed support with an active partnering process with several major pharma companies.

Challenge A division of a multinational pharma company needed support evaluating a pipeline agreement with a platform technology company. The client wanted to know what the overall value of this...

Challenge A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with preclinical testing on pigs,...

Challenge A company considering an investment in a new early-stage biosensor technology for the measurement of blood pressure needed due diligence support. The product had a number of potential...

Challenge A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment.

Challenge Our client asked us to conduct a risk assessment and due diligence of a small molecule oncology compound that had been identified from a phenotypic screen. The molecule was in a Phase I/II...

Challenge We were commissioned to conduct a comprehensive technical risk assessment and due diligence of a novel preclinical, small molecule, kinase inhibitor.